Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Selectins01:25

Selectins

3.4K
Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative binding and activity analysis of known serine hydroxymethyltransferase inhibitors in biochemical assays.

RSC advances·2026
Same author

Fusion Molecules Between the STAT5b Inhibitor Stafib-2-CR and a Cereblon Ligand.

ChemistryOpen·2026
Same author

Stafib-2-CR: an Improved Nanomolar and Selective Inhibitor of the Transcription Factor STAT5b Developed by Conformational Restriction of Stafib-2.

Chemistry (Weinheim an der Bergstrasse, Germany)·2025
Same author

Biaryl Phosphate-Based Inhibitors of the Transcription Factor STAT4.

ChemMedChem·2025
Same author

Activity Analysis of the P2X Receptor Antagonist PPADS against Signal Transducer and Activator of Transcription Proteins.

Chembiochem : a European journal of chemical biology·2025
Same author

Biaryl Phosphates and Phosphonates as Selective Inhibitors of the Transcription Factor STAT4.

Angewandte Chemie (International ed. in English)·2025

Related Experiment Video

Updated: Aug 23, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.9K

Stafiba: A STAT5-Selective Small-Molecule Inhibitor.

Katrin S Eckhardt1, Theresa Münzel1, Julian Gräb1

  • 1Leipzig University, Institute of Organic Chemistry, Johannisallee 29, 04103, Leipzig, Germany.

Chembiochem : a European Journal of Chemical Biology
|October 27, 2022
PubMed
Summary

Researchers developed Stafiba, a stable inhibitor targeting STAT5a and STAT5b proteins, crucial in many human tumors. This advancement offers a promising new strategy for cancer therapy by blocking these key tumor-promoting factors.

Keywords:
SH2 domainsbiological activityinhibitorsprotein-protein interactionstranscription factors

More Related Videos

A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput
12:22

A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput

Published on: September 22, 2019

8.6K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Related Experiment Videos

Last Updated: Aug 23, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.9K
A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput
12:22

A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput

Published on: September 22, 2019

8.6K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Area of Science:

  • Molecular Biology
  • Oncology
  • Drug Discovery

Background:

  • Signal transducer and activator of transcription 5a (STAT5a) and STAT5b are transcription factors frequently constitutively active in human tumors.
  • Combined inhibition of STAT5a and STAT5b presents a promising therapeutic strategy in tumor biology.
  • Previous research identified resorcinol bisphosphate as a moderately active inhibitor of STAT5a/b SH2 domains.

Purpose of the Study:

  • To develop a more stable and potent inhibitor of STAT5a and STAT5b based on the resorcinol bisphosphate scaffold.
  • To investigate the structure-activity relationships of resorcinol bisphosphate derivatives as STAT5 inhibitors.

Main Methods:

  • Chemical synthesis and modification of resorcinol bisphosphate derivatives.
  • Biochemical assays to determine inhibitory activity against STAT5a and STAT5b SH2 domains.
  • Assessment of phosphatase stability of the developed inhibitors.

Main Results:

  • Development of Stafiba, a novel inhibitor derived from resorcinol bisphosphate.
  • Stafiba demonstrates enhanced stability against phosphatases compared to its precursor.
  • Stafiba exhibits inhibitory activity in the low micromolar concentration range against STAT5a and STAT5b.

Conclusions:

  • Stafiba represents a significant advancement over resorcinol bisphosphate as a STAT5 inhibitor.
  • The developed inhibitor is phosphatase-stable and effective at low micromolar concentrations.
  • Structure-activity relationship insights guide the future design of STAT5a/b inhibitors for cancer therapy.